REFERENCES
1. Human Genetics Society of Australasia. Counting conditions and summary of conditions screened by programme. Available from: https://hgsa.org.au/common/Uploaded%20files/pdfs/policies,%20position%20statements%20and%20guidelines/newborn%20screening/2023%20PL01%20Counting%20Conditions%20and%20Summary%20of%20Conditions%20Screened%20by%20Programme..pdf [Last accessed on 21 Nov 2023].
3. The Department of Health and Aged Care. Population-based screening framework. Available from: https://www.health.gov.au/resources/publications/population-based-screening-framework?language=en [Last accessed on 21 Nov 2023].
4. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organisation;1968. Available from: https://niercheck.nl/wp-content/uploads/2019/06/Wilson-Jungner-1968.pdf [Last accessed on 21 Nov 2023].
5. Coman D, Bhattacharya K. Extended newborn screening: an update for the general paediatrician. J Paediatr Child Health 2012;48:E68-72.
6. Franková V, Driscoll RO, Jansen ME, et al; Members of the European Society of Human Genetics (ESHG)-EuroGentest Quality Sub-Committee. Regulatory landscape of providing information on newborn screening to parents across Europe. Eur J Hum Genet 2021;29:67-78.
7. Australian Health Ministers’ Advisory Council. Newborn bloodspot screening national policy framework. Available from: https://www.health.gov.au/sites/default/files/documents/2020/10/newborn-bloodspot-screening-national-policy-framework.pdf [Last accessed on 21 Nov 2023].
8. Kariyawasam D, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med 2020;22:557-65.
9. Kariyawasam DS, D'Silva AM, Sampaio H, et al. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc Health 2023;7:159-70.
10. Dangouloff T, Boemer F, Servais L. Newborn screening of neuromuscular diseases. Neuromuscul Disord 2021;31:1070-80.
11. Shih STF, Keller E, Wiley V, Wong M, Farrar MA, Chambers GM. Economic evaluation of newborn screening for severe combined immunodeficiency. Int J Neonatal Screen 2022;8:44.
12. Shih STF, Keller E, Wiley V, Farrar MA, Wong M, Chambers GM. Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency. Int J Neonatal Screen 2022;8:45.
13. Huang X, Wu D, Zhu L, et al. Application of a next-generation sequencing (NGS) panel in newborn screening efficiently identifies inborn disorders of neonates. Orphanet J Rare Dis 2022;17:66.
14. Godler DE, Ling L, Gamage D, et al. Feasibility of screening for chromosome 15 imprinting disorders in 16 579 newborns by using a novel genomic workflow. JAMA Netw Open 2022;5:e2141911.
15. Bourmaud A, Gallien S, Domon B. Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: principle and applications. Proteomics 2016;16:2146-59.
16. Holm IA, Agrawal PB, Ceyhan-Birsoy O, et al; BabySeq Project Team. The babySeq project: implementing genomic sequencing in newborns. BMC Pediatr 2018;18:225.
17. Roman TS, Crowley SB, Roche MI, et al. Genomic sequencing for newborn screening: results of the NC NEXUS project. Am J Hum Genet 2020;107:596-611.
18. Ceyhan-Birsoy O, Murry JB, Machini K, et al; BabySeq Project Team. Interpretation of genomic sequencing results in healthy and ill newborns: results from the babyseq project. Am J Hum Genet 2019;104:76-93.
19. Sagan A, McDaid D, Rajan S, Farrington J, McKee M. Screening: when is it appropriate and how can we get it right? Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559794/ [Last accessed on 21 Nov 2023].
20. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
21. Andermann A, Blancquaert I, Beauchamp S, Costea I. Guiding policy decisions for genetic screening: developing a systematic and transparent approach. Public Health Genomics 2010;14:9-16.
22. Andermann A, Blancquaert I, Déry V. Genetic screening: a conceptual framework for programmes and policy-making. J Health Serv Res Policy 2010;15:90-7.
23. Arah OA, Klazinga NS, Delnoij DM, ten Asbroek AH, Custers T. Conceptual frameworks for health systems performance: a quest for effectiveness, quality, and improvement. Int J Qual Health Care 2003;15:377-98.
24. Australian Institute of Health and Welfare. Health expenditure Australia 2020-21. Available from: https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2020-21/contents/spending-trends-by-sources [Last accessed on 21 Nov 2023].
25. Cao M, Notini L, Ayres S, Vears DF. Australian healthcare professionals' perspectives on the ethical and practical issues associated with genomic newborn screening. J Genet Couns 2023;32:376-86.
26. Metz MP, Ranieri E, Gerace RL, Priest KR, Luke CG, Chan A. Newborn screening in South Australia: is it universal? Med J Aust 2003;179:412-5.
27. Nolan-Isles D, Macniven R, Hunter K, et al. Enablers and barriers to accessing healthcare services for aboriginal people in New South Wales, Australia. Int J Environ Res Public Health 2021;18:3014.
28. D'Silva AM, Kariyawasam DST, Best S, Wiley V, Farrar MA; NSW SMA NBS Study Group. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol 2022;64:625-32.
29. Therrell BL, Padilla CD, Loeber JG, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol 2015;39:171-87.
30. Department of Health and Aged Care. Expansion of newborn bloodspot screening. Available from: https://www.health.gov.au/our-work/newborn-bloodspot-screening/expansion [Last accessed on 21 Nov 2023].
31. Commonwealth of Australia. The new frontier - delivering better health for all Australians. Available from: https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Newdrugs/Report [Last accessed on 21 Nov 2023].
32. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;348:2304-12.
33. Hall PL, Marquardt G, Mchugh DM, et al. Postanalytical tools improve performance of newborn screening by tandem mass spectrometry. Genet Med 2014;16:889-95.
34. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Rodney Howell R. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8 Suppl 1:1S-252S.
35. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003;111:1399-406.
36. Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis 2021;44:566-92.
37. Hertzog A, Selvanathan A, Pandithan D, et al. 3-Methylglutaconyl-CoA hydratase deficiency: when ascertainment bias confounds a biochemical diagnosis. JIMD Rep 2022;63:568-74.
38. Thompson S, Hertzog A, Selvanathan A, et al. Treatment of HMG-CoA lyase deficiency-longitudinal data on clinical and nutritional management of 10 australian cases. Nutrients 2023;15:531.
39. Rüfenacht V, Häberle J. Mini-review: challenges in newborn screening for urea cycle disorders. Int J Neonatal Screen 2015;1:27-35.
40. California Department of Public Health. NEwborn screening program: disorders detectable by newborn screening. Available from: https://www.cdph.ca.gov/Programs/CFH/DGDS/Pages/nbs/NBS-Disorders-Detectable.aspx [Last accessed on 21 Nov 2023].
41. Ryder B, Inbar-Feigenberg M, Glamuzina E, et al. New insights into carnitine-acylcarnitine translocase deficiency from 23 cases: management challenges and potential therapeutic approaches. J Inherit Metab Dis 2021;44:903-15.
42. Health Resources & Services Administration. Previously nominated conditions. Available from: https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/previous-nominations [Last accessed on 21 Nov 2023].
43. Department of Health and Aged Care. What is screened in the program. Available from: https://www.health.gov.au/our-work/newborn-bloodspot-screening/what-is-screened [Last accessed on 21 Nov 2023].
44. Department of Health and Aged Care. Delivering newborn bloodspot screening programs. Available from: https://www.health.gov.au/our-work/newborn-bloodspot-screening/delivering-programs [Last accessed on 21 Nov 2023].
45. Farrar MA, Kiernan MC. Spinal muscular atrophy - the dawning of a new era. Nat Rev Neurol 2020;16:593-4.
46. McPherson E. Postcode lottery: The screening test saving babies in some states but not others. Available from: https://www.9news.com.au/national/newborn-screening-australia-postcode-lottery-calls-for-heel-prick-test-to-be-expanded/39cad501-9109-4855-8c59-e30c700903a1 [Last accessed on 21 Nov 2023].
47. Newborn screening: a blueprint for the future executive summary: newborn screening task force report. Pediatrics 2000;106:386-8.
48. Bhattacharya K, Millis N, Jaffe A, Zurynski Y. Rare diseases research and policy in Australia: On the journey to equitable care. J Paediatrics Child Health 2021;57:778-81.
49. Australian Government Department of Health and Aged Care. National strategic action plan for rare diseases. Available from: https://www.health.gov.au/resources/publications/national-strategic-action-plan-for-rare-diseases [Last accessed on 21 Nov 2023].
50. Department of Health and Aged Care. MRFF genomics health futures mission implementation plan. Available from: https://www.health.gov.au/resources/publications/mrff-genomics-health-futures-mission-implementation-plan?language=en [Last accessed on 21 Nov 2023].
51. Australian Genomics. Genomic screening consortium for australian newborns (GenSCAN). Available from: https://www.australiangenomics.org.au/projects/genomic-screening-consortium-for-australian-newborns-genscan/ [Last accessed on 21 Nov 2023].
52. Kingsmore SF, Smith LD, Kunard CM, et al. A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases. Am J Hum Genet 2022;109:1605-19.
53. Owen MJ, Lefebvre S, Hansen C, et al. An automated 13.5 hour system for scalable diagnosis and acute management guidance for genetic diseases. Nat Commun 2022;13:4057.
54. Nurchis MC, Altamura G, Riccardi MT, et al. Whole genome sequencing diagnostic yield for paediatric patients with suspected genetic disorders: systematic review, meta-analysis, and GRADE assessment. Arch Public Health 2023;81:93.
55. Sachdev R, Field M, Baynam GS, et al. Paediatric genomic testing: navigating medicare rebatable genomic testing. J Paediatr Child Health 2021;57:477-83.
56. Burdick KJ, Cogan JD, Rives LC, et al; Undiagnosed Diseases Network. Limitations of exome sequencing in detecting rare and undiagnosed diseases. Am J Med Genet A 2020;182:1400-6.
57. Kirk EP, Ong R, Boggs K, et al. Gene selection for the Australian reproductive genetic carrier screening project (“Mackenzie's Mission”). Eur J Hum Genet 2021;29:79-87.
58. Vears DF, Savulescu J, Christodoulou J, Wall M, Newson AJ. Are we ready for whole population genomic sequencing of asymptomatic newborns? Pharmgenomics Pers Med 2023;16:681-91.
59. White S, Mossfield T, Fleming J, et al. Expanding the Australian newborn blood spot screening program using genomic sequencing: do we want it and are we ready? Eur J Hum Genet 2023;31:703-11.
60. Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA; members of the NSIGHT Ethics and Policy Advisory Board. Sequencing newborns: a call for nuanced use of genomic technologies. Hastings Center Report 2018; 48 Suppl 2:S2-6.
61. Ross LF, Clayton EW. Ethical issues in newborn sequencing research: the case study of babyseq. Pediatrics 2019;144:e20191031.
63. Botkin JR, Rothwell E. Whole genome sequencing and newborn screening. Curr Genet Med Rep 2016;4:1-6.
64. Woerner AC, Gallagher RC, Vockley J, Adhikari AN. The use of whole genome and exome sequencing for newborn screening: challenges and opportunities for population health. Front Pediatr 2021;9:663752.
65. Newson AJ. The promise of public health ethics for precision medicine: the case of newborn preventive genomic sequencing. Hum Genet 2022;141:1035-43.
66. Pichini A, Ahmed A, Patch C, et al. Developing a national newborn genomes program: an approach driven by ethics, engagement and co-design. Front Genet 2022;13:866168.
67. Bhattacharjee A, Sokolsky T, Wyman SK, et al. Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing. Genet Med 2015;17:337-47.
68. Easteal S, Arkell RM, Balboa RF, et al; National Centre for Indigenous Genomics. Equitable expanded carrier screening needs indigenous clinical and population genomic data. Am J Hum Genet 2020;107:175-82.
69. Ko JM, Park KS, Kang Y, et al. A new integrated newborn screening workflow can provide a shortcut to differential diagnosis and confirmation of inherited metabolic diseases. Yonsei Med J 2018;59:652-61.
70. Wojcik MH, Zhang T, Ceyhan-Birsoy O, et al; BabySeq Project Team. Discordant results between conventional newborn screening and genomic sequencing in the babyseq project. Genet Med 2021;23:1372-5.
71. Downie L, Halliday J, Lewis S, Amor DJ. Principles of genomic newborn screening programs: a systematic review. JAMA Netw Open 2021;4:e2114336.
72. Walker CE, Mahede T, Davis G, et al. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genetics in Medicine 2017;19:546-52.
73. Downie L, Halliday J, Lewis S, et al. Exome sequencing in newborns with congenital deafness as a model for genomic newborn screening: the baby beyond hearing project. Genet Med 2020;22:937-44.
74. Genetti CA, Schwartz TS, Robinson JO, et al; BabySeq Project Team. Parental interest in genomic sequencing of newborns: enrollment experience from the babyseq project. Genet Med 2019;21:622-30.
75. Martin AR, Williams E, Foulger RE, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat Genet 2019;51:1560-5.
76. Yeung A, Christodoulou J, Amor D, et al. Baby Screen+ newborn screening (version 1.108). Available from: https://panelapp.agha.umccr.org/panels/3931/ [Last accessed on 21 Nov 2023].
77. Johnson F, Ulph F, MacLeod R, Southern KW. Receiving results of uncertain clinical relevance from population genetic screening: systematic review & meta-synthesis of qualitative research. Eur J Hum Genet 2022;30:520-31.
78. Boardman F, Clark C. 'We're kind of like genetic nomads': prents' experiences of biographical disruption and uncertainty following in/conclusive results from newborn cystic fibrosis screening. Soc Sci Med 2022;301:114972.
79. Esquerda M, Palau F, Lorenzo D, et al. Ethical questions concerning newborn genetic screening. Clin Genet 2021;99:93-8.
80. Financial Services Council. FSC Standard No. 11: moratorium on genetic tests in life insurance. Available from: www.fsc.org.au/resources-category/standard/1779-standard-11-moratorium-on-genetic-tests-in-life-insurance/file [Last accessed on 21 Nov 2023].
81. Dhondt JL. Expanded newborn screening: social and ethical issues. J Inherit Metab Dis 2010;33:S211-7.
82. Zacharias RL, Smith ME, King JS. The legal dimensions of genomic sequencing in newborn screening. Hastings Cent Rep 2018;48 Suppl 2:S39-41.
83. Lakes KD, Vaughan E, Lemke A, et al. Maternal perspectives on the return of genetic results: context matters. Am J Med Genet A 2013;161A:38-47.
84. Verma IC, Saxena R, Kohli S. Past, present & future scenario of thalassaemic care & control in India. Indian J Med Res 2011;134:507-21.
85. Medical Services Advisory Committee. About MSAC. Available from: http://msac.gov.au/internet/msac/publishing.nsf/Content/about-msac [Last accessed on 21 Nov 2023].
86. Medical Services Advisory Committee. Guidelines for preparing assessments for the Medical Services Advisory Committee. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/E0D4E4EDDE91EAC8CA2586E0007AFC75/$File/MSAC%20Guidelines-complete-16-FINAL(18May21).pdf [Last accessed on 21 Nov 2023].
87. Potter BK, Avard D, Entwistle V, et al. Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report. Public Health Genomics 2009;12:4-10.
88. Potter BK, Avard D, Graham ID, et al. Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. Int J Technol Assess Health Care 2008;24:412-22.
89. Rahimzadeh V, Friedman JM, de Wert G, Knoppers BM. Exome/genome-wide testing in newborn screening: a proportionate path forward. Front Genet 2022;13:865400.
90. Pharmaceutical Benefits Advisory Committee. About the guidelines. Available from: https://pbac.pbs.gov.au/information/about-the-guidelines.html [Last accessed on 21 Nov 2023].
91. Medical Services Advisory Committee. Application No. 1573 - reproductive carrier testing for cystic fibrosis, spinal muscular atrophy and fragile X syndrome. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/4EF0E3C5A7CC9D05CA2584240009557E/$File/1573%20-%20Final%20PSD_Jul2020.pdf [Last accessed on 21 Nov 2023].
92. Medical Services Advisory Committee. Application No. 1637 - expanded reproductive carrier testing of couples for joint carrier status of genes associated with autosomal recessive and X-linked conditions. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/58B9ED94DEC5BCDECA2586D500054D7E/$File/1637%20Final%20PSD_Jul2022_redacted_UpdatedConsultation_clean.pdf [Last accessed on 21 Nov 2023].
93. Ulph F, Bennett R. Psychological and ethical challenges of introducing whole genome sequencing into routine newborn screening: lessons learned from existing newborn screening. New Bioeth 2023;29:52-74.
94. Williams WA 2nd, Ross LF. The Harms of Carrier Status Identification: a cautionary warning against newborn sequencing. J Pediatr 2020;224:22-3.
95. Goldenberg AJ, Lloyd-Puryear M, Brosco JP, et al; Bioethics and Legal Workgroup of the Newborn Screening Translational Research Network. Including ELSI research questions in newborn screening pilot studies. Genet Med 2019;21:525-33.
96. Currier RJ. Newborn screening is on a collision course with public health ethics. Int J Neonatal Screen 2022;8:51.
97. Kemper AR, Boyle CA, Brosco JP, Grosse SD. Ensuring the life-span benefits of newborn screening. Pediatrics 2019;144:e20190904.
98. Sen K, Harmon J, Gropman AL. Select ethical aspects of next-generation sequencing tests for newborn screening and diagnostic evaluation of critically Ill newborns. Int J Neonatal Screen 2021;7:76.
99. Clark CC, Boardman FK. Expanding the notion of “benefit”: comparing public, parent, and professional attitudes towards whole genome sequencing in newborns. New Genetics and Society 2022;41:96-115.
